Market Newsdesk

Atlanta, GA, March 30, 2021 (GLOBE NEWSWIRE) — Neuravest Research, a provider of AI-driven portfolio construction solutions for institutional investors, today announced that Seth Merrin has joined the organization as the firm’s Executive Chairman. A globally renown entrepreneur, business leader and author, Seth has launched numerous successful FinTech companies during a 35-year career, including two that profoundly changed the institutional investment industry, Merrin Financial and, most recently, Liquidnet.

“We are extremely pleased and fortunate to have our technology and business model vetted and validated by someone of Seth’s caliber of innovation and experience,” said Katz. “Seth understands the challenges institutional investors face today as they strive to differentiate themselves and deliver a unique performance advantage. His entire career has been built around the concept of removing friction in the financial markets to improve capital formation, enhance investment performance, and ultimately increase returns for both institutions and the individuals they represent.”

“What is truly exciting about Neuravest is the seven years of technology build and AI capability that has gone into its platform, which can rapidly ingest raw data, validate its predictive power, and deploy to market single strat, multi strat, correlated, and non-correlated production-ready investment strategies,” said Merrin. “The ability to quickly discern among the massive amounts of predictive and non-predictive data provides an enormous competitive advantage that grows with every new value-added data set. The amount of data available continues to accelerate and the technology to process, learn, and analyze it for predictive qualities continues to grow exponentially. Unfortunately, you can’t really say that about human beings. We are offering these solutions to asset managers, hedge funds, pension funds, endowments, and wealth managers around the globe.”

Merrin’s role within this new venture coincides with his departure from Liquidnet, the company he founded in 1999 and served as its Chairman and CEO. Under Merrin’s leadership, Liquidnet grew from a singularly focused equity block-execution platform to a global institutional trading and investing network, connecting more than 1,000 of the world’s top asset management firms across 45 financial markets and six continents. Most recently, Merrin orchestrated Liquidnet’s expansion into AI-based investment decision support, focusing on delivering actionable market intelligence and insight to fund managers worldwide. Liquidnet announced in October 2020 its plans to be acquired by TP ICAP, and Merrin stepped down as Executive Chairman on March 24, shortly after the deal closed.

Merrin founded his first company, Merrin Financial, in 1985, launching the industry’s first order management, compliance, and electronic order routing systems for asset managers. Merrin also co-founded BridgeBio Pharma, a Nasdaq-traded biotech company focused on advancing transformative medicines for major genetic diseases, and Ignite Solar, the fastest-growing solar-energy provider in Africa.

In addition to his role as Executive Chairman, Merrin is also the lead investor in Neuravest and has personally committed capital to the Neuravest models.

“My investment in Neuravest is based on the belief and knowledge that sustainable, superior performance can only be accomplished through AI technology, machine learning and data,” said Merrin. “It was also born from the need to manage my assets responsibly and efficiently. I was so impressed with their technology I wanted to own the company.”

About Neuravest

Neuravest empowers asset managers across the globe to deliver superior fund performance by applying machine learning and data science to portfolio construction and management. Launched in 2021 as a successor to Lucena Research, Neuravest takes AI-based investment insight and decision support to the next level by designing and delivering pre-configured thematic portfolios and bespoke investment models using best-in-class alternative data sources. To Learn more, visit www.neuravest.net.

Richard Franco
Forefront Communications for Neuravest Research
917.309.8951
[email protected]

GAITHERSBURG, MD, March 30, 2021 (GLOBE NEWSWIRE) — Sodexo, a food service and facilities management company committed to providing quality of life, announced a first-of-its-kind partnership today with HelloFresh, the world’s leading meal kit company, to offer delivery of HelloFresh and EveryPlate meal kits to students at more than 300 U.S. colleges and universities.

Using Sodexo’s BiteU app, students can pre-select, order and schedule meal kits for delivery. Whether students are vegetarian, on a low-calorie diet, or looking for something quick and easy, HelloFresh gives them the flexibility to select meals from an extensive rotating weekly menu. EveryPlate offers an ever-changing menu of simplistic, delicious, and affordable chef-curated recipes with vegetarian and gourmet options. Meal kits arrive with fresh, pre-measured ingredients, step-by-step instructions, and all the necessary tools to get dinner together in 30 minutes or less. Students have the option to cancel, change, or skip orders at any time.

“Our campus dining program is focused on enabling choice and convenience,” said Kevin Rettle, vice president, global offer development and digital innovation, Sodexo Universities and Schools. “Our partnership with HelloFresh allows us to expand our resident dining experience and provide an affordable, family meal-style option for students and customers.”

“We are excited to partner with Sodexo to bring both our HelloFresh and EveryPlate brand meal kits to college campuses across the country,” said Andreas Sossong, vice president, strategic projects at HelloFresh US. “Busy students should have a convenient, affordable way to enjoy delicious, homecooked meals with high quality ingredients. We look forward to introducing this unique cooking experience to students at additional campuses throughout the year.”

Sodexo’s on-campus food and retail outlets are powered by its BiteU app. Created internally by Sodexo’s technology and university teams, the BiteU app connects back-end card systems to make meal plans and payment options seamless and creates a safe, cashless environment across campuses. Since launching, BiteU has been deployed at 40 percent of Sodexo-serviced sites. It will achieve 80 percent deployment by August 2021.

About HelloFresh

HelloFresh SE is the world’s leading meal-kit company and operates in the U.S., the United Kingdom, Germany, the Netherlands, Belgium, Luxembourg, Australia, Austria, Switzerland, Canada, New Zealand, Sweden, France and Denmark. In 2020, HelloFresh delivered over 600 million meals and reached close to 5.3 million active customers. HelloFresh was founded in Berlin in November 2011 and went public on the Frankfurt Stock Exchange in November 2017. HelloFresh has offices in New York, Berlin, London, Amsterdam, Sydney, Toronto, Auckland, Paris and Copenhagen.

 

About Sodexo North America

Sodexo North America is part of a global, Fortune 500 company with a presence in 64 countries. Sodexo is a leading provider of integrated food, facilities management and other services that enhance organizational performance, contribute to local communities and improve quality of life for millions of customers in corporate, education, healthcare, senior living, sports and leisure, government and other environments daily. Sodexo is committed to supporting diversity and inclusion and safety, while upholding the highest standards of corporate responsibility and ethical business conduct. In support of local communities across the U.S., in 2020, the Sodexo Stop Hunger Foundation mobilized 10,000 Sodexo volunteers to distribute 4.1 million meals to help 5.9 million children and adults meet their immediate food needs. Since 1996, the Stop Hunger Foundation has contributed $36.7 million to help feed children in America impacted by hunger. To learn more about Sodexo, visit us.sodexo.com, and connect with us on Facebook, Instagram, LinkedIn, Twitter and YouTube.

 

Attachment

• HelloFresh_BOX (2)

Dasha Ross-Smith
Sodexo
[email protected]

NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the closing of the Royalty, License and Termination agreement (the “Agreement”) under which Takeda Pharmaceutical secured global rights from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.

At closing, Ovid received an upfront payment of $196 million and is eligible to receive up to an additional $660 million upon achieving development, regulatory and sales milestones. In addition, Ovid will receive tiered double-digit royalties, up to 20 percent on sales of soticlestat, if approved and commercialized. Takeda has assumed sole responsibility for further worldwide development and commercialization, and Ovid no longer has any financial obligation to Takeda under the original collaboration agreement, including for milestone payments or any future development and commercialization costs.

About Soticlestat (TAK-935/OV935)

Soticlestat is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor and modulates glutamatergic signaling associated with epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve distorted excitatory/inhibitory balance in the brain.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders.  We believe these disorders represent an attractive area for drug development as the understanding of the underlying biology has grown meaningfully over the last few years and today represents a substantial opportunity medically and commercially. Based on recent scientific advances in genetics and the biological pathways of the brain, we aim to identify, discover and acquire novel compounds for the treatment of rare neurological disorders. We have built a deep knowledge of such disorders, how to treat them and how to develop the clinically meaningful endpoints required for development of a compound in these disorders. We continue to execute on our strategy to build this pipeline by discovering, in-licensing and collaborating with leading biopharmaceutical companies and academic institutions. These pipeline programs include programs targeting rare epilepsies, Angelman syndrome and Fragile X syndrome, as well as early-stage programs into other monogenetic disorders. Ovid’s emerging pipeline programs include OV329, a small molecule GABA aminotransferase inhibitor for seizures associated with Tuberous Sclerosis Complex and Infantile Spasms; OV882, a short hairpin RNA therapy approach for Angelman syndrome; OV815, a genetic therapy approach for KIF1A associated neurological disorder; and other non-disclosed research targets. Additionally, Ovid maintains a financial interest in OV935 which is now being developed by Takeda. For more information on Ovid, please visit www.ovidrx.com.

Ovid Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the potential benefits, clinical and regulatory development and commercialization of soticlestat and Ovid’s programs and the potential value, benefits, and outcome of the Royalty, License and Termination Agreement with Takeda. You can identify forward-looking statements because they contain words such as “will,” “appears,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available, and the ability to commercialize soticlestat. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors.” Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid’s business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts

Investors and Media:

Ovid Therapeutics Inc.
Investor Relations & Public Relations
[email protected]

OR

Investors:

Argot Partners
Dawn Schottlandt
212-600-1902
[email protected]

Media:

Dan Budwick
1AB
[email protected]

March 30, 2021  

Philips received a score of 90 out of 100, the highest that S&P Global Ratings has awarded to date

Amsterdam, the Netherlands –

Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that its strategy to do business responsibly and sustainably has been validated by S&P Global Ratings. Evaluated across the Environmental, Social and Governance (ESG) dimensions of S&P Global Ratings’ assessment, Philips received a score of 90 out of 100, the highest that S&P Global Ratings has awarded to date.  

“As a purpose-driven company, we are conscious of our responsibility towards society and of the need to continue to embed ESG practices ever deeper in the way we do business,” said Frans van Houten, CEO of Royal Philips. “I am proud that this commitment has again been recognized externally, receiving the highest score to date in the S&P Global Ratings ESG Evaluation. This sends a strong message to investors and our other stakeholders, who increasingly look to a company’s ESG actions as a measure of its commitment to doing business in a responsible and sustainable manner.”

S&P Global Ratings’ ESG Evaluation assesses a company’s ESG strategy and ability to prepare for potential future risks and opportunities and is used by investors as a forward looking, long-term opinion of a company’s readiness for disruptive ESG risks and opportunities. It provides an overall ESG Score that allows comparison with other entities globally, including sector peers.

“Our ESG Evaluation score of 90 reflects our view that sustainability is at the core of Philips’ corporate strategy,” states S&P Global Ratings in its evaluation report. “The company built a digital, integrated, and solution-based business model before most of its global peers, which it leverages to respond to key challenges in the health care industry, such as inequality in the access and affordability of care, and shortages of medical professionals.”

In the Environmental domain, S&P Global Ratings notes that “Philips applies leading environmental standards across its value chain” and “distinguishes itself in the management of its indirect environmental impact.” It also recognizes that “Philips has a track record of setting and achieving more ambitious targets in its direct operations than many of its industry peers.”

In the Social domain, Philips is recognized for being “better positioned than many industry peers to provide access to medical care to customers and communities because of its diversified regional footprint and portfolio of products and services.” The report also applauds “Philips’ commitment to pay a living wage to all its staff…”, and recognizes that “its management of human rights risk in its supply chain sets the company apart from peers.”

For Governance, S&P Global Ratings notes that “Philips’ governance structure follows the Dutch Corporate Governance Code…”, which the report views as “aligned with international best practices”. The evaluation also notes that “Philips has comprehensive financial and sustainability disclosures audited by an external auditor…”, including “policies on most material environmental and social risks, and approaches used to calculate key performance indicators, including green revenue and millions of lives improved.”

Enhanced ESG framework

In September 2020, as part of its ongoing commitment to making the world healthier and more sustainable through innovation, Philips launched an enhanced and fully integrated approach to doing business responsibly and sustainably. This framework comprises a comprehensive set of targets, commitments, and action plans across all the Environmental, Social and Governance dimensions that will drive further growth while acting responsibly towards the planet and society.

The full report is available here.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 15213446
E-mail: [email protected]

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: [email protected]

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Refurbishment Process MRI
• Bouwdokken
• CLC South-Africa

NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the U.S. Food and Drug Administration (FDA) has allowed evaluation of nasal administration with Foralumab, a fully human anti-CD3 monoclonal antibody, in a secondary progressive multiple sclerosis (SPMS) patient at the Brigham and Women’s Hospital (BWH), Harvard University, Boston, MA. This patient will be treated under an Individual Patient Expanded Access IND. This is the first time a nasally administered antibody will be administered to a patient with SPMS. The treatment is planned to start in the second quarter of 2021, and will continue for six months. Investigators at BWH will follow this patient with detailed routine safety, neurological, imaging and PET studies to evaluate microglial imaging. Modification of immunological and neurodegenerative markers is part of standard investigations that will be conducted at the BWH.

Previously, Tiziana completed a Phase 1 trial of a single-site, double-blind, placebo-controlled, multiple ascending dose (MAD) once a day dosing for 5 consecutive days with nasally administered Foralumab in healthy subjects. The treatment was well-tolerated with no drug-related safety issues reported at any doses up to 250 mg of the doses.   Nasal foralumab was developed by Professor Howard Weiner at BWH.

Weiner commented, “Nasal anti-CD3 is an exciting, novel approach that has the ability to provide a safe treatment for a form of MS that has no effective treatment. We are pleased that the FDA has allowed us to treat a patient with SPMS who needs a better treatment option than is currently available.”

Dr. Tanuja Chitnis, Professor of Neurology at Harvard Medical School and senior neurologist at the BWH, adds, “New treatments for progressive MS are urgently needed. Nasal Foralumab could revolutionize treatment for this disabling form of disease.” 

The company had previously reported positive data from the Clinical Study of Nasal Administration with Foralumab in COVID-19 patients in Brazil. Nasally administered Foralumab at 100 mg/day for consecutive 10 days treatment was found to be well-tolerated, and there were no apparent severe adverse events. The clinical data suggested that the treatment provided significant reduction of lung inflammation.

About Foralumab

Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients with Crohn’s disease with decreases in the classic side effects of cytokine release syndrome and improves the overall safety profile of Foralumab. In a humanized mouse model (NOD/SCID IL2γc-/-), it was shown that whilst targeting the T cell receptor, orally administered Foralumab modulates immune responses of the T cells, enhances regulatory T-cells (Tregs) and thus provides therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy (Ogura M. et al., 2017). Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of Tregs.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA, UK LSE: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to Milciclib, the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn’s Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (“mAb”) in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (“T1D”), inflammatory bowel disease (“IBD”), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (“IL6R”) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

For further enquiries: United Kingdom: Tiziana Life Sciences plc    +44 (0)20 7495 2379 Gabriele Cerrone, Chairman and founder

United States: Investors: Dave Gentry, CEO RedChip Companies Inc. 1-800-RED-CHIP (733-2447) or 407-491-4498 [email protected]

BURLINGTON, Mass., March 30, 2021 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today announced that its Cerence Drive conversational AI platform is now available on Android Automotive OS, giving automakers the ability to build custom, OEM-branded, conversational assistants atop the Android Automotive OS stack for the first time. This new offering from Cerence delivers capabilities that are most important to automakers: ownership over their unique brand experience, control over vehicle and driver data, and integrated coexistence and usability among multiple big tech ecosystems.

Cerence is deeply committed to coexistence and interoperability among the various big tech and general-purpose assistant ecosystems and has transformed its Cerence Drive platform into a truly OS-agnostic offering. With Cerence’s best-in-class conversational AI built on top of Android Automotive OS, automakers can now ensure their native digital assistants can seamlessly coexist with Google Automotive Services, including Google Assistant, without compromising brand ownership and while preserving the unique in-car experience they’ve built for their drivers. Automakers also maintain deep visibility into driver usage and interactions, providing them with rich data for improvements, updates, and continued innovation.

“The Cerence Drive platform layered on the Android Automotive OS removes barriers and obstacles for OEMs looking to create an exceptional branded and connected experience for drivers,” said Sanjay Dhawan, CEO, Cerence. “By taking a completely OS-agnostic approach to uniting these two platforms, Cerence delivers true coexistence of ecosystems in the car – an ‘and’ rather than ‘either/or’ approach – that creates a safer and more intuitive experience for drivers.”

By running Cerence Drive on Android Automotive OS, OEMs can position their Cerence-powered, custom-branded in-car assistant as the main interactive interface for their drivers. With a deep integration layer between Cerence Drive and Android Automotive OS Voice Interaction Service, drivers get a best-in-class experience with multi-intent support, along with multi-seat intelligence, speech signal enhancement, and noise cancellation. This gives OEMs and their drivers the best of both worlds – a highly intelligent and customizable mobility conversational AI assistant built on decades of automotive industry experience that harnesses the power of the full-stack, open-source Android Automotive OS.

“The race for voice in the car continues, with leading automakers increasingly seeking brand differentiation via personalized voice controls,” said Fahad Hamid, Senior Connected Car Specialist at SBD Automotive. Added Hamid, “To ensure interoperability and be considered for wider deployment, voice solution providers need to work across disparate platforms and ecosystems of the automaker’s choosing.”

The recently launched Cerence Drive 2.0 fully adheres to Android Automotive OS specifications and utilizes the Android Automotive OS Voice Interaction Service natively to enable the Cerence-powered voice assistant as a default assistant in car. It also enables interaction and invocation through various other means, including custom-branded wake-up word, push-to-talk using a physical voice control button typically located on the steering wheel, or tap-to-talk using a software voice control button as part of the system user interface.

To learn more about Cerence, visit www.cerence.com, and follow the company on LinkedIn and Twitter.

About Cerence Inc.

Cerence (NASDAQ: CRNC) is the global industry leader in creating unique, moving experiences for the mobility world. As an innovation partner to the world’s leading automakers and mobility OEMs, it is helping advance the future of connected mobility through intuitive, powerful interaction between humans and their cars, two-wheelers, and even elevators, connecting consumers’ digital lives to their daily journeys no matter where they are. Cerence’s track record is built on more than 20 years of knowledge and more than 350 million cars shipped with Cerence technology. Whether it’s connected cars, autonomous driving, e-vehicles, or buildings, Cerence is mapping the road ahead. For more information, visit www.cerence.com.

Trademark reference: Cerence and the Cerence logo are registered trademarks or trademarks of Cerence Inc. or its affiliates in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners.

Android is a trademark of Google LLC.

Contact Information

Kate Hickman
Cerence Inc.
Tel: 339-215-4583
Email: [email protected]

TORONTO, March 30, 2021 (GLOBE NEWSWIRE) — B2B gaming technology platform provider Bragg Gaming Group (TSX:BRAG, OTC: BRGGF) (“Bragg” or the “Company“) announced today that the wholly-owned subsidiary ORYX Gaming has signed a licensing and revenue sharing agreement with Grand Casino Baden, Switzerland’s first licensed online casino operator and now one of the leading online gambling sites in Switzerland

The operator’s online casino brand, jackpots.ch, will provide content from ORYX’s exclusive RGS partner, GAMOMAT. Titles include top-performing Royal Seven, Ramses Book, Crystal Book and Take 5, all of which offer features and jackpots focused on increasing player engagement and retention.

The content provided by ORYX will be integrated into the Player Account Management Platform of Gamanza, the market leading online casino technology provider in the newly regulated Swiss market.

ORYX was awarded an ISO/IEC 27001 certificate in 2020, considered a regulation benchmark in Switzerland. ORYX is licensed by the Malta Gaming Authority (MGA) and the Romanian National Gambling Office (ONJN) and its content is certified or approved in 18 other major jurisdictions.

“Partnering with yet another Swiss operator is another step toward our goal of increasing our footprint in Switzerland throughout Europe,” said Matevž Mazij, Managing Director of ORYX Gaming. “The content we offer is the perfect fit for Swiss players, and our seamless integration makes it easy for online casino operators like Grand Casino Baden to add our games to their platform and increase their audience and player engagement, ultimately increasing revenue.”

“We have had a strong start to our online operations thanks to the wide, diverse and entertaining content we have to offer,” added Marcel Tobler, Chief Strategy Officer at Grand Casino Baden. “By partnering with ORYX our customers will gain access to the innovative and fun titles that will resonate well with slot fans. We’re excited about this revenue sharing agreement.”

About Bragg Gaming Group

Bragg Gaming Group (TSX:BRAG, OTC: BRGGF) is a global B2B gaming technology platform provider. With operations across Europe and North America, Bragg is expanding into an international force within the burgeoning global online gaming market. Bragg’s main brand is ORYX Gaming, an innovative business-to-business iGaming platform, casino content aggregator, managed sportsbook and managed services provider, offering cutting-edge content from leading studios.

For Bragg Gaming Group, contact:

Yaniv Spielberg, CSO, Bragg Gaming Group
[email protected]

For media enquiries or interviews, please contact:

Keera Hart, Kaiser & Partners Communications
[email protected]
905.580.1257

For investor enquiries, please contact:

David Gentry 
[email protected]
1-800-733-2447
407-491-4498

Cautionary Statement Regarding Forward-Looking Information

This news release may contain forward-looking statements or “forward-looking information” within the meaning of applicable Canadian securities laws (“forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or describes a “goal”, or variation of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

All forward-looking statements reflect the Company’s beliefs and assumptions based on information available at the time the statements were made. Actual results or events may differ from those predicted in these forward-looking statements. All of the Company’s forward-looking statements are qualified by the assumptions that are stated or inherent in such forward-looking statements, including the assumptions listed below. Although the Company believes that these assumptions are reasonable, this list is not exhaustive of factors that may affect any of the forward-looking statements. The key assumptions that have been made in connection with the forward-looking statements include the following: the impact of COVID-19 on the business of the Company; the countercyclical growth of the business of the Company; the regulatory regime governing the business of the Company; the operations of the Company; the products and services of the Company; the Company’s customers; acquisition opportunities; the growth of the Company’s business, which may not be achieved or realized within the time frames stated or at all; and the anticipated size and/or revenue associated with the gaming market globally.

Forward-looking statements involve known and unknown risks, future events, conditions, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, prediction, projection, forecast, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, the following: risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; the inability to access sufficient capital from internal and external sources; the inability to access sufficient capital on favourable terms; realization of growth estimates, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; economic and financial conditions, including volatility in interest and exchange rates, commodity and equity prices; the estimated size of the gaming market globally; changes in customer demand; disruptions to our technology network including computer systems and software; natural events such as severe weather, fires, floods and earthquakes; and risks related to health pandemics and the outbreak of communicable diseases, such as the current outbreak of COVID-19.

Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Any forward-looking statement made by the Company in this news release or the earnings call is based only on information currently available to the Company and speaks only as of the date on which it is made. Except as required by applicable securities laws, the Company nor any of its management or directors undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Non-IFRS Financial Measures

Statements in this news release make reference to “Adjusted EBITDA”, which is a non-IFRS (as defined herein) financial measure that the Company believes is appropriate to provide meaningful comparison with, and to enhance an overall understanding of, the Company’s past financial performance and prospects for the future. The Company believes that “Adjusted EBITDA” provides useful information to both management and investors by excluding specific expenses and items that management believe are not indicative of the Company’s core operating results. “Adjusted EBITDA” is a financial measure that does not have a standardized meaning under International Financial Reporting Standards (“IFRS”). As there is no standardized method of calculating “Adjusted EBITDA”, it may not be directly comparable with similarly titled measures used by other companies. The Company considers “Adjusted EBITDA” to be a relevant indicator for measuring trends in performance and its ability to generate funds to service its debt and to meet its future working capital and capital expenditure requirements. “Adjusted EBITDA” is not a generally accepted earnings measure and should not be considered in isolation or as an alternative to net income (loss), cash flows or other measures of performance prepared in accordance with IFRS.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this news release. 

NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) — The Board of Directors of Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Henry A. Fernandez as Lead Independent Director. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc. Mr. Fernandez will continue to serve on the Audit Committee of Royalty Pharma plc.

“We are further strengthening the governance of Royalty Pharma with this new key role,” stated Pablo Legorreta, founder, CEO and Chairman of Royalty Pharma. “Henry has a record of exceptional leadership having led MSCI from a nascent index business to a leading global provider of critical decision support tools for the investment community. Henry has demonstrated tremendous business acumen, a strong entrepreneurial spirit, unwavering integrity and a clear focus on corporate responsibility. During his tenure at MSCI, he has delivered significant value creation for all stakeholders. Royalty Pharma will benefit greatly from Henry’s extensive experience as we continue to build upon our unique leadership position at the heart of funding biopharma innovation to improve the lives of patients globally,” Legorreta added.

“I am honored to be selected for this Board role,” said Henry A. Fernandez. “I have observed the high caliber of the people at Royalty Pharma and the strength of the business model as a longtime shareholder and as a Board member since August 2020. I look forward to providing strong independent oversight as Lead Independent Director.”

About Henry A. Fernandez

Henry A. Fernandez has served as Director and Chairman of MSCI Inc. since 2007 and as Chief Executive Officer since 1998. Before leading MSCI’s transition to becoming a fully independent, public company in 2007, he was a Managing Director at Morgan Stanley from 1983 to 1991 and from 1994 to 2007, where he worked in emerging markets product strategy, equity derivative sales and trading, mergers and acquisitions, worldwide corporate finance and mortgage finance for U.S. financial institutions. Mr. Fernandez serves on the Board of Trustees for Stanford University as well as Memorial Sloan Kettering Cancer Center. Mr. Fernandez holds a Bachelor of Arts in economics from Georgetown University, an M.B.A. from the Stanford University Graduate School of Business and pursued doctoral studies in economics at Princeton University.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
[email protected]

BOSTON, March 30, 2021 (GLOBE NEWSWIRE) — Atlan is launching a new webinar series featuring some of the most impactful tools needed to create a modern data platform — a term that is being increasingly used to describe the best of breed tools and capabilities to help create fully self-service & agile data driven organizations.

The webinar series will feature best practices in building modern data platforms through live case studies, and features of leading tools in the modern data stack such as Snowflake, Looker, Starburst, Great Expectations & Atlan.

To kick the first webinar off, Atlan will be partnering with Snowflake to showcase how users can build a modern data stack using Snowflake’s platform and Atlan’s modern data catalog & governance product.

“With the integration of Snowflake and Atlan, we are building the firm foundation of a modern data platform. Snowflake customers love the agility that we bring to their data operations. Now with Atlan, they can go a step further and truly democratize data by enabling every user to discover, understand & trust all their data assets,” says Jeremy Maranitch, Senior Alliance Manager at Snowflake.

“By integrating Atlan with Snowflake, even non-technical users can now easily discover data & query data on Snowflake without knowing SQL! Data engineers are able to track column level lineage from source to business intelligence, and measure data quality across their data platform. All within 30 mins of setup,” says Prukalpa Sankar, Cofounder at Atlan.

Anticipated audience members include CDOs, Head of Data Governance & Management, Head of Analytics, Data Science & Machine Learning, and Data Platform/Data Engineering leaders.

Atlan plans to continue this webinar series on a monthly cadence throughout the year.

About Atlan:
Atlan is a modern data collaboration workspace enabling better collaboration between diverse users like business, analysts and engineers. By acting as a virtual hub for data assets ranging from tables and dashboards to models & code, Atlan enables teams to create a single source of truth for all their data assets and collaborate across the modern data stack through deep integrations with tools like Slack, Tableau, Looker, Jupyter and more.

A pioneer in the space, Atlan was recognized by Gartner as a Cool Vendor in DataOps, as one of the top 3 companies globally. Atlan.com

Contacts:

For media inquiries:

Stepheni Hass
Director, Marketing Operations
Formulatedby
+1 512-520-7169
[email protected]

SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bispecific antibody technology, jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for initiating phase 1 trial for bispecific antibody TJ-CD4B/ABL111. The phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ-CD4B/ABL111 in advanced or metastatic solid tumors.

TJ-CD4B/ABL111 is a novel bispecific antibody that works through binding to a tumor antigen Claudin 18.2 (CLDN18.2) which is selectively expressed in several cancers and to 4-1BB, a co-stimulatory molecule expressed on T cells, to activate immune response within tumor for better anti-tumor activity. Preclinical studies demonstrate that TJ-CD4B/ABL111 has superior anti-tumor property as compared to the two monoclonal antibodies when acting alone or in combination. This superior anti-tumor activity is achieved locally on tumor site, thus minimizing the risk of liver and systemic side effects commonly associated with 4-1BB antibody when used alone.

“With its high specificity and novel properties, TJ-CD4B/ABL111 could have significant advantages over other 4-1BB monoclonal antibodies in terms of the efficacy and toxicities. It could become a key player against various advanced cancers. We are very excited about the initiation of the clinical study and hope to bring this highly valuable compound to the cancer patients with the critical unmet needs,” said Dr. Taylor Guo, chief scientific officer of I-Mab.

“With the FDA approval of the IND application to initiate a phase 1 clinical trial of TJ-CD4B/ABL111, we expect to progress rapidly with the clinical development of TJ-CD4B/ABL111,” said Dr. Sang Hoon Lee, Founder and CEO of ABL. “In partnership with I-Mab, we look forward to providing a superior therapeutic option for patients with advanced and metastatic solid cancers.”

The phase 1 clinical study will be a multi-center, dose escalation study in the U.S. I-Mab also plans to conduct dose expansion studies for TJ-CD4B/ABL111 in patients with gastric cancers, gastro-esophageal junction adenocarcinoma, esophageal adenocarcinoma and pancreatic ductal adenocarcinoma in China later this year.

About TJ-CD4B/ABL111

TJ-CD4B, also known as ABL111, is a Claudin 18.2 and 4-1BB bispecific antibody capable of binding to tumor cells expressing Claudin 18.2, i.e., gastric cancer and pancreatic cancer cells, and stimulating intra-tumoral T cells by the 4-1BB arm designed to be activated only upon tumor engagement whilst silent elsewhere. TJ-CD4B effectively maintains a strong tumor binding property and anti-tumor activity attributable to a synergistic effect of both Claudin 18.2 antibody and 4-1BB antibody while it avoids or minimizes liver toxicity and systemic immunotoxicity commonly seen with 4-1BB antibodies as a drug class. TJ-CD4B is being developed under collaboration between I-Mab and ABL.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company’s mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab’s globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company’s unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter and WeChat.

About ABL Bio

ABL Bio, Inc. (Kosdaq: 298380) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com

I-Mab Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from the TJ-CD4B clinical trials, the potential implications of clinical data for patients, and the advancement by I-Mab and ABL, and anticipated clinical development, regulatory milestones and commercialization of TJ-CD4B. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to the ability of I-Mab and ABL to demonstrate the safety and efficacy of TJ-CD4B; the clinical results for the drug candidate, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the drug candidate; the ability to achieve commercial success for the drug candidate, if approved; I-Mab’s ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab’s reliance on third parties to conduct drug development, manufacturing and other services; I-Mab’s limited operating history and I-Mab’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in I-Mab’s most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in I-Mab’s subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to I-Mab, and I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

ABL Forward Looking Statements

Statements in this press release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform act of 1995. Words such as “will,” “could,” “hope,” “expect,” “plan” and similar expressions that are based on ABL’s current expectations and assumptions are subject to risks and uncertainties that are difficult to predict. The risks and uncertainties include but are not limited to, potential delays in clinical trial recruitment and participation; ABL and I-Mab’s ability to demonstrate the safety and efficacy of ABL111; adverse results in the clinical development process; changes in expected or existing competition; changes in the biopharmaceutical landscape; ABL’s ability to obtain and maintain protection of intellectual property for its technology and drugs; ABL’s reliance on third parties to conduct drug development; the company’s financial position; future decisions by the FDA or other regulatory authorities; volatile global economic conditions; and the impact of the global COVID-19 pandemic. The reader is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to ABL and the company assumes no obligation to provide public updates to these forward-looking statements that are only as of the date of this press release, even if new information is available in the future.

For more information, please contact:

I-Mab
Jielun Zhu, Chief Financial Officer
E-mail: [email protected]
Office line: +86 21 6057 8000

Gigi Feng, Chief Communications Officer
E-mail: [email protected]
Office line: +86 21 6057 5785

Investor Inquiries:

The Piacente Group, Inc.

Emilie Wu
E-mail: [email protected]
Office line: +86 21 6039 8363

ABL Contacts

Jaecheon Jerry Lee
Chief Financial Officer
[email protected]
+82 31 8018 9802

Investor Inquiries:

Hyunjun Kim
[email protected]
+82 31 8018 9845